Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis.
Fiche du document
18 décembre 2019
- doi: 10.3390/diagnostics10010002
- issn: 2075-4418
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3390/diagnostics10010002
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31861469
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2075-4418
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_287C68962BA47
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Mots-clés
PET; culprit tumor; detection rate; meta-analysis; osteomalacia; somatostatin; systematic reviewSujets proches
Tumours Neoplasms Growth hormone release inhibiting factor SRIH (Hormone) Thyrotropin release inhibiting factor Somatotropin release inhibiting hormone Follicle stimulating hormone release inhibiting factor Growth hormone inhibitory hormoneCiter ce document
M. Meyer et al., « Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis. », Serveur académique Lausannois, ID : 10.3390/diagnostics10010002
Métriques
Partage / Export
Résumé
Tumor-induced or oncogenic osteomalacia (TIO) is a rare paraneoplastic syndrome in which osteomalacia is a consequence of fibroblast growth factor 23 (FGF23) secretion by a mesenchymal tumor. The localization of the culprit lesion in patients with TIO is often challenging. Several studies have evaluated the detection rate (DR) of these tumors using somatostatin receptor positron emission tomography (SSTR-PET/CT). We aimed to summarize literature findings on this topic providing pooled estimates of DR. A comprehensive literature search by screening PubMed, Embase and Cochrane library electronic databases through August 2019 was performed. The pooled DR of culprit tumors using SSTR-PET/CT in patients with TIO was calculated using a random-effects statistical model. Fourteen studies on the use of SSTR-PET/CT in detecting the culprit tumor in patients with TIO were included in the qualitative analysis. The pooled DR of SSTR-PET/CT on a per-patient-based analysis calculated using eleven studies (166 patients) was 87.6% (95% confidence interval (95% CI) 80.2-95.1%). Statistical heterogeneity among studies was detected (I-square = 63%), likely due to the use of different radiolabeled somatostatin analogues, as demonstrated by a subgroup analysis. Despite limited literature data due to the rarity of the disease, SSTR-PET/CT demonstrated a very high DR of culprit tumors in patients with TIO and it could be used as first-line imaging method for this indication.